Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 6.15B 5.5B 5.08B 4.6B 8.62B 585B 8.76B 61.19B 24.2B 306B 23.07B 22.57B 968B P/E 2026 *
58.5x
P/E 2027 * 35.9x
Enterprise Value 6.15B 5.5B 5.08B 4.6B 8.62B 585B 8.76B 61.19B 24.2B 306B 23.07B 22.57B 968B EV / Sales 2026 *
21.3x
EV / Sales 2027 * 16.1x
Free-Float
97.68%
Yield 2026 *
-
Yield 2027 * -
1 day+1.57%
1 week+3.71%
Current month-1.30%
1 month+2.25%
3 months+2.59%
6 months+33.31%
Current year+63.06%
1 week 302.37
Extreme 302.37
317.64
1 month 281.74
Extreme 281.7401
317.64
Current year 175.89
Extreme 175.89
326.63
1 year 175.89
Extreme 175.89
326.63
3 years 49.79
Extreme 49.7902
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 04/12/2022
Director of Finance/CFO 47 20/05/2015
Director of Finance/CFO 56 31/10/2022
Director TitleAgeSince
Chairman 76 28/02/2003
Director/Board Member 57 26/09/2006
Director/Board Member 65 28/02/2007
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Exercice

General Counsel

5,680 0.0285%
22/09/26 Tax

Director

-115 0.0006%
10/09/26 Sell

Director

-1,200 0.0060%
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%+3.71%+64.88%+503.80% 6.05B
+0.45%+3.13%+54.96%+125.16% 1,135B
+0.94%+4.93%+39.86%+78.72% 635B
+0.39%+1.44%+25.77%+97.48% 505B
+1.43%+4.31%+46.20%+67.12% 378B
-3.21%-2.10%+60.72%+33.22% 358B
-0.41%+2.64%+22.48%+49.82% 295B
+0.23%+3.66%+2.57%+23.69% 266B
+1.22%+4.63%+52.40%+64.85% 237B
+1.70%+3.67%+31.21%+102.15% 193B
Average +0.40%+2.88%+40.11%+114.60% 400.97B
Weighted average by Cap. +0.42%+2.85%+41.44%+84.24%

Financials

2026 *2027 *
Net sales 289M 258M 239M 216M 405M 27.49B 412M 2.88B 1.14B 14.38B 1.08B 1.06B 45.52B 382M 341M 316M 286M 535M 36.31B 544M 3.8B 1.5B 18.99B 1.43B 1.4B 60.13B
Net income 113M 101M 93.07M 84.27M 158M 10.7B 160M 1.12B 443M 5.6B 422M 413M 17.73B 188M 168M 155M 141M 263M 17.85B 267M 1.87B 739M 9.34B 704M 689M 29.57B
Net Debt - -
Projected Income Statement - Annual - Ligand Pharmaceuticals Incorporated
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
26/10/26 US$308.30 +1.57% 194,779
23/10/26 US$303.53 -1.39% 366,546
22/10/26 US$307.82 -2.21% 315,135
21/10/26 US$314.78 +2.73% 222,759
20/10/26 US$306.40 +3.07% 171,729
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ligand Pharmaceuticals Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
308.30USD
Average target price
345.75USD
Spread / Average Target
+12.15%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ligand Pharmaceuticals Incorporated
  1. Stock Market
  2. Stocks
  3. LGND Stock